PMID- 27354485
OWN - NLM
STAT- MEDLINE
DCOM- 20170721
LR  - 20220419
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 34
IP  - 25
DP  - 2016 Sep 1
TI  - Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung 
      Cancer.
PG  - 2980-7
LID - 10.1200/JCO.2016.66.9929 [doi]
AB  - PURPOSE: Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor 
      antibody, has demonstrated improved survival over docetaxel in previously treated 
      advanced non-small-cell lung cancer (NSCLC). First-line monotherapy with 
      nivolumab for advanced NSCLC was evaluated in the phase I, multicohort, Checkmate 
      012 trial. METHODS: Fifty-two patients received nivolumab 3 mg/kg intravenously 
      every 2 weeks until progression or unacceptable toxicity; postprogression 
      treatment was permitted per protocol. The primary objective was to assess safety; 
      secondary objectives included objective response rate (ORR) and 24-week 
      progression-free survival (PFS) rate; overall survival (OS) was an exploratory 
      end point. RESULTS: Any-grade treatment-related adverse events (AEs) occurred in 
      71% of patients, most commonly: fatigue (29%), rash (19%), nausea (14%), diarrhea 
      (12%), pruritus (12%), and arthralgia (10%). Ten patients (19%) reported grade 3 
      to 4 treatment-related AEs; grade 3 rash was the only grade 3 to 4 event 
      occurring in more than one patient (n = 2; 4%). Six patients (12%) discontinued 
      because of a treatment-related AE. The confirmed ORR was 23% (12 of 52), 
      including four ongoing complete responses. Nine of 12 responses (75%) occurred by 
      first tumor assessment (week 11); eight (67%) were ongoing (range, 5.3+ to 25.8+ 
      months) at the time of data lock. ORR was 28% (nine of 32) in patients with any 
      degree of tumor PD-ligand 1 expression and 14% (two of 14) in patients with no 
      PD-ligand 1 expression. Median PFS was 3.6 months, and the 24-week PFS rate was 
      41% (95% CI, 27 to 54). Median OS was 19.4 months, and the 1-year and 18-month OS 
      rates were 73% (95% CI, 59 to 83) and 57% (95% CI, 42 to 70), respectively. 
      CONCLUSION: First-line nivolumab monotherapy demonstrated a tolerable safety 
      profile and durable responses in first-line advanced NSCLC.
CI  - (c) 2016 by American Society of Clinical Oncology.
FAU - Gettinger, Scott
AU  - Gettinger S
AD  - Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew 
      D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, 
      University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, 
      Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, 
      NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; 
      Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. 
      Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. 
      Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. 
      Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, 
      University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun 
      Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ. 
      scott.gettinger@yale.edu.
FAU - Rizvi, Naiyer A
AU  - Rizvi NA
AD  - Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew 
      D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, 
      University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, 
      Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, 
      NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; 
      Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. 
      Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. 
      Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. 
      Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, 
      University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun 
      Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.
FAU - Chow, Laura Q
AU  - Chow LQ
AD  - Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew 
      D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, 
      University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, 
      Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, 
      NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; 
      Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. 
      Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. 
      Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. 
      Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, 
      University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun 
      Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.
FAU - Borghaei, Hossein
AU  - Borghaei H
AD  - Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew 
      D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, 
      University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, 
      Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, 
      NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; 
      Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. 
      Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. 
      Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. 
      Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, 
      University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun 
      Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.
FAU - Brahmer, Julie
AU  - Brahmer J
AD  - Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew 
      D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, 
      University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, 
      Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, 
      NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; 
      Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. 
      Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. 
      Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. 
      Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, 
      University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun 
      Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.
FAU - Ready, Neal
AU  - Ready N
AD  - Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew 
      D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, 
      University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, 
      Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, 
      NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; 
      Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. 
      Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. 
      Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. 
      Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, 
      University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun 
      Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.
FAU - Gerber, David E
AU  - Gerber DE
AD  - Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew 
      D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, 
      University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, 
      Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, 
      NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; 
      Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. 
      Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. 
      Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. 
      Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, 
      University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun 
      Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.
FAU - Shepherd, Frances A
AU  - Shepherd FA
AD  - Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew 
      D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, 
      University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, 
      Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, 
      NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; 
      Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. 
      Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. 
      Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. 
      Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, 
      University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun 
      Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.
FAU - Antonia, Scott
AU  - Antonia S
AD  - Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew 
      D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, 
      University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, 
      Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, 
      NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; 
      Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. 
      Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. 
      Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. 
      Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, 
      University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun 
      Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.
FAU - Goldman, Jonathan W
AU  - Goldman JW
AD  - Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew 
      D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, 
      University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, 
      Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, 
      NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; 
      Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. 
      Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. 
      Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. 
      Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, 
      University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun 
      Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.
FAU - Juergens, Rosalyn A
AU  - Juergens RA
AD  - Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew 
      D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, 
      University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, 
      Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, 
      NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; 
      Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. 
      Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. 
      Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. 
      Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, 
      University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun 
      Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.
FAU - Laurie, Scott A
AU  - Laurie SA
AD  - Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew 
      D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, 
      University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, 
      Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, 
      NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; 
      Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. 
      Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. 
      Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. 
      Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, 
      University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun 
      Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.
FAU - Nathan, Faith E
AU  - Nathan FE
AD  - Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew 
      D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, 
      University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, 
      Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, 
      NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; 
      Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. 
      Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. 
      Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. 
      Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, 
      University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun 
      Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.
FAU - Shen, Yun
AU  - Shen Y
AD  - Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew 
      D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, 
      University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, 
      Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, 
      NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; 
      Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. 
      Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. 
      Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. 
      Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, 
      University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun 
      Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.
FAU - Harbison, Christopher T
AU  - Harbison CT
AD  - Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew 
      D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, 
      University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, 
      Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, 
      NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; 
      Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. 
      Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. 
      Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. 
      Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, 
      University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun 
      Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.
FAU - Hellmann, Matthew D
AU  - Hellmann MD
AD  - Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew 
      D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, 
      University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, 
      Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at 
      Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, 
      NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; 
      Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. 
      Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. 
      Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. 
      Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, 
      University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun 
      Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.
LA  - eng
SI  - ClinicalTrials.gov/NCT01454102
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Clinical Trial, Phase I
PT  - Journal Article
DEP - 20160627
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
CIN - J Clin Oncol. 2016 Sep 1;34(25):2953-5. PMID: 27382094
CIN - Nat Rev Clin Oncol. 2016 Oct;13(10 ):595-6. PMID: 27620712
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal/adverse effects/*therapeutic use
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Nivolumab
PMC - PMC5569692
COIS- Authors' disclosures of potential conflicts of interest are found in the article 
      online at www.jco.org. Author contributions are found at the end of this article.
EDAT- 2016/06/30 06:00
MHDA- 2017/07/22 06:00
PMCR- 2016/10/01
CRDT- 2016/06/30 06:00
PHST- 2016/06/30 06:00 [entrez]
PHST- 2016/06/30 06:00 [pubmed]
PHST- 2017/07/22 06:00 [medline]
PHST- 2016/10/01 00:00 [pmc-release]
AID - JCO.2016.66.9929 [pii]
AID - 669929 [pii]
AID - 10.1200/JCO.2016.66.9929 [doi]
PST - ppublish
SO  - J Clin Oncol. 2016 Sep 1;34(25):2980-7. doi: 10.1200/JCO.2016.66.9929. Epub 2016 
      Jun 27.